A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered updates ...

CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. CellPryme-A acts ...

Welcome to the second installment of "Cancer and the Gut Microbiome: A Miniseries". Here, we focus on how the microbiome ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...